GE HealthCare Technologies Inc. - Common Stock (GEHC)

GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand.

GE HealthCare (Nasdaq: GEHC) has been named to 2025 Fortune World’s Most Admired Companies™ list. The company has been recognized across several categories including the quality of management, products and services, innovation, value as a long-term investment, financial soundness, talent acquisition and retention, community and environmental responsibility, global business, and use of corporate assets.

GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the updated portfolio of Voluson™ Expert Series ultrasound systems. Voluson Expert 22, 20 and 18 combine high resolution image quality with advanced ultrasound technology and an ergonomic design for efficient workflow and a world-class user experience. The Voluson Expert Series integrates artificial intelligence (AI)-powered features and automation tools to help drive imaging performance and efficiencies in women’s healthcare.

University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE HealthCare today announced the launch of a Care Innovation Hub, a joint research collaboration that aims to address meaningful clinical challenges in three key areas: accessibility to advanced medical imaging, non-invasive diagnosis and management of neurological and neurodegenerative disease, and precision oncology. The Care Innovation Hub leverages the strengths of academia and industry to create, evaluate and translate novel technology into a clinical setting with the goals of advancing diagnosis and treatment of disease, improving hospital operations and driving more equitable access to care.

Sutter Health and GE HealthCare (Nasdaq: GEHC) today announced a seven-year strategic enterprise partnership, known as a Care Alliance, that aims to increase access to innovative imaging services and create a more seamless and coordinated experience for clinicians and patients across the Sutter Health system. The long-term collaboration will increase access to essential diagnostic care across California, providing patients with advanced technology in their own communities that can help enable quicker appointment scheduling, accelerated diagnostic imaging scan results, early diagnoses, greater convenience, and more consistent and timely care. This Care Alliance marks one of GE HealthCare's largest ever enterprise strategic partnerships.

GE HealthCare (Nasdaq: GEHC) will announce its fourth quarter and full year 2024 financial results before the market opens on Thursday, February 13, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.

GE HealthCare (Nasdaq: GEHC) unveiled three new advanced deep learning image processing and reconstruction solutions as a part of its Effortless Recon DL portfolio at the Radiological Society of North America (RSNA) 2024 Annual Meeting, in Chicago, IL. Understanding the need to improve operational efficiencies within radiology departments and the ongoing challenge of burnout experienced by clinicians, GE HealthCare developed the technologies to deliver exceptional image quality, reduce scan times, and support improved patient outcomes.

As part of a companywide commitment to advance innovation that improves the health of patients and the planet, GE HealthCare (Nasdaq: GEHC) is highlighting several solutions with increased focus on sustainability at the Radiological Society of North America (RSNA) 2024 Annual Meeting, which is held Dec. 1-4 in Chicago, IL.

GE HealthCare (Nasdaq: GEHC) announced today the 510(k) submission to the U.S. Food and Drug Administration for CleaRecon DL, deep learning technology, designed to improve the quality of cone-beam computed tomography (CBCT) images by bringing artificial intelligence (AI)-based 3D reconstruction to the interventional suite. This technology, which is pending 510(k) clearance, will be demonstrated at the Radiological Society of North America’s (RSNA) 2024 Annual Meeting taking place from December 1-4 in Chicago.

GE HealthCare (Nasdaq: GEHC) has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical (TYO: 4005) the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertise developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Sumitomo and GE HealthCare expect the agreement to close in early 2025, subject to regulatory approvals.

GE HealthCare (Nasdaq: GEHC) today unveiled Sonic DL for 3Dii, the newest addition to its effortless imaging portfolio, designed to accelerate MRI scans across a wide range of clinical applications. Sonic DL for 3D builds on GE HealthCare’s deep learning innovation legacy and the success of AIR Recon DL, which has helped over 34 million patients to date. Initially launched in 2023 for Cardiac MRI, Sonic DL provides up to 12 times scan acceleration while maintaining diagnostic qualityiii. Now, GE HealthCare is extending Sonic DL to 3D volumetric imaging, designing it to broaden its applicability to brain, spine, orthopedic and body exams, in addition to cardiac. This expansion is intended to retain the same impressive 12x acceleration and reduce scan times by up to 86%.

At the Radiological Society of North America’s (RSNA) 2024 Annual Meeting taking place from Dec. 1-4 in Chicago, GE HealthCare (Nasdaq: GEHC) will exhibit more than 40 innovations, including several key artificial intelligence (AI)-enabled technologies to optimize patient care and increase operational efficiencies.

Today GE HealthCare announced the new Pristina Via™* mammography system designed to enhance the screening experience for both technologists and patients. Debuting at the Radiological Society of North America’s 2024 Annual Meeting, this innovation provides mammography technologists with a suite of sophisticated tools that balance the demands of diagnostic accuracy and fast-paced workflows to facilitate more patient-centered breast care.

GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conferences.

GE HealthCare (Nasdaq: GEHC) announces additional clinical applications now available as part of the OEC 3D mobile CBCT C-arm portfolio to help enable precise and efficient imaging during endoscopic bronchoscopy procedures in the practice of interventional pulmonology.

GE HealthCare (Nasdaq: GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance.

GE HealthCare (Nasdaq: GEHC) today announced the publication of data from a two-phase pilot study conducted with Cleveland Clinic in the peer-reviewed Journal of Clinical Anesthesia, highlighting performance of the wireless and wearable Portrait™ Mobile monitoring solution in the post-surgical ward environment.

GE HealthCare (Nasdaq: GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS,i a 3.0T high-performance, head-only magnetic resonance imaging (MRI) scanner. This system offers new capabilities for both clinical imaging and neuroscience with the potential to aid in the detection of neurological, oncological, and psychiatric conditions.

GE HealthCare (Nasdaq: GEHC) today announced an initiative with AMN Healthcare aimed at helping address the critical shortage of radiologic technologists (rad tech) in the healthcare industry. This initiative helps healthcare providers meet their immediate staffing needs through AMN Healthcare’s comprehensive workforce solutions and GE HealthCare’s innovative technologies and training expertise.

EQNX::TICKER_START (OTCQB:AVAI),(NYSEBFLY),NASDAQ:TEMNASDAQTEM)(NASDAQ:GEHCNASDAQGEHC,(NASDAQ:RDNTNASDAQ) EQNX::TICKER_END

Today, GE HealthCare (Nasdaq: GEHC) and DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), announced a strategic collaboration to further the innovation, commercialization, and adoption of AI in imaging. Together, the two companies aim to develop SmartTechnology™ solutions that harness the transformative power of AI to address key challenges across the imaging value chain, including helping increase the efficiency of imaging interpretation and reporting, enabling collaboration across care teams, improving the clinical interpretation of images, and enhancing operational efficiency and productivity. These new SmartTechnology solutions will seek to combine GE HealthCare’s imaging expertise and scale, RadNet’s deep experience in care delivery, and DeepHealth’s AI-powered health informatics portfolio to elevate patient care through improved end-to-end clinical and operational workflows.

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

GE HealthCare (Nasdaq: GEHC) will host its Investor Day on Thursday, November 21, 2024, at Nasdaq MarketSite in New York, NY, where its management team will present its growth strategies, technology portfolio, and vision for its businesses. A technology showcase will follow the presentations for in-person attendees. Registration is required.

GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2024.